Double-blind clinical evaluation of a new anti-inflammatory drug, protacine, versus indomethacin.


A double-blind clinical trial was carried out in 69 rheumatic in-patients to compare the efficacy and tolerance of a new, non-steroidal anti-inflammatory agent, protacine, with that of indomethacin. Patients received either 150 mg protacine or 50 mg indomethacin 3-times daily for 21 days. The time course of symptoms was recorded by semiquantitative scoring… (More)


  • Presentations referencing similar topics